EUVIMEDEUVIMED entdecken
Crossref

Role of the Stockholm3 Test in Guiding Confirmation Biopsy Decisions for Patients with Prostate Cancer on Active Surveillance

Serdar Madendere, Mert Kılıç, Erhan Palaoğlu, Mert Veznikli, Metin Vural, Ayşenur İğdem, Derya Tilki, Tarık Esen, Derya Balbay

European Urology Focus · 2025

DOI: 10.1016/j.euf.2025.06.016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Urology Focus, 2025. Verfasst von Serdar Madendere und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, VKV American Hospital, Istanbul, Türkiye. Electronic address: serdarmadendere@gmail.com. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Watchful Waiting, Multiparametric Magnetic Resonance Imaging, Prostate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: The aim of our study was to assess correlation between Stockholm3 test results, multiparametric magnetic resonance imaging (mpMRI) findings, and confirmation biopsy outcomes in a cohort of patients on active surveillance (AS) for prostate cancer (PC). METHODS: The study cohort comprised 26 patients on AS for International Society of Urological Pathology grade group (GG) 1 PC. Repeat MRI and confirmation biopsy following a Stockholm3 test were performed for all. We defined a Stockholm3 score cutoff of ≥15 for higher risk of clinically significant PC (csPC). The sensitivity and negative predictive value (NPV) of the Stockholm3 test and mpMRI for prediction of csPC were assessed. KEY FINDINGS AND LIMITATIONS: The median age for the study cohort was 63 yr. Median PSA was 4.6 ng/ml and the median Stockholm3 score was 17. Sixteen patients (61.5%) had lesion with a Prostate Imaging-Reporting and Data System (PI-RADS) score of ≥4 on repeat mpMRI. Confirmatory biopsy revealed benign histology in five patients (19.3%), GG 1 PC in 13 patients (50%), and GG >1 PC (upgrading) in eight patients (30.7%). Using a score cutoff of ≥15 for the Stockholm3 test yielded sensitivity of 87.5% and an NPV of 90% for upgrading on confirmatory biopsy. Of 16 patients with a PI-RADS ≥4 lesion on MRI, 43.7% had csPC on confirmatory biopsy. PI-RADS ≥4 had sensitivity of 87.5% and an NPV of 90% for prediction of csPC. CONCLUSIONS AND CLINICAL IMPLICATIONS: For most of our 26 patients on AS with a Stockholm3 score of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsWatchful WaitingMultiparametric Magnetic Resonance ImagingProstateHumansMaleMiddle AgedAgedBiopsyPredictive Value of TestsSensitivity and SpecificityImage-Guided BiopsyProstate-Specific Antigen

Stichwörter der Autor:innen

Multiparametric magnetic resonance imagingProstate cancerStockholm3 test

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, VKV American Hospital, Istanbul, Türkiye. Electronic address: serdarmadendere@gmail.com.
  • Department of Urology, VKV American Hospital, Istanbul, Türkiye.
  • Department of Biochemistry, VKV American Hospital, Istanbul, Türkiye.
  • Department of Biostatistics, Koç University School of Medicine, Istanbul, Türkiye.
  • Department of Radiology, VKV American Hospital, Istanbul, Türkiye.
  • Department of Pathology, VKV American Hospital, Istanbul, Türkiye.

Zitieren

APA

Madendere, S., Kılıç, M., Palaoğlu, E., Veznikli, M., Vural, M., İğdem, A., Tilki, D., Esen, T., & Balbay, D. (2025). Role of the Stockholm3 Test in Guiding Confirmation Biopsy Decisions for Patients with Prostate Cancer on Active Surveillance. European Urology Focus. https://doi.org/10.1016/j.euf.2025.06.016

Vancouver

Madendere S, Kılıç M, Palaoğlu E, Veznikli M, Vural M, İğdem A, et al. Role of the Stockholm3 Test in Guiding Confirmation Biopsy Decisions for Patients with Prostate Cancer on Active Surveillance. European Urology Focus. 2025. doi:10.1016/j.euf.2025.06.016

BibTeX
@article{Madendere2025,
  author = {Madendere, Serdar and Kılıç, Mert and Palaoğlu, Erhan and Veznikli, Mert and Vural, Metin and İğdem, Ayşenur and Tilki, Derya and Esen, Tarık and Balbay, Derya},
  title = {Role of the Stockholm3 Test in Guiding Confirmation Biopsy Decisions for Patients with Prostate Cancer on Active Surveillance},
  journal = {European Urology Focus},
  year = {2025},
  doi = {10.1016/j.euf.2025.06.016}
}
Kostenlos starten →